


EMGALITY® IS THE

**ONLY CGRP ANTIBODY FDA APPROVED**WITH SPECIFIC DOSES FOR BOTH MIGRAINE AND EPISODIC CLUSTER HEADACHE<sup>1,2</sup>**EPISODIC AND CHRONIC MIGRAINE<sup>1</sup>**

- **Method of administration:** Pen or prefilled syringe
- **Monthly dosing strength:** 120 mg

Recommended dosing for Emgality—no titration required<sup>1a</sup>**LOADING DOSE<sup>1</sup>:**


- Month 1: **240 mg** (2 consecutive SC injections of 120 mg each) once as a loading dose
- 2 packages with the same NDC must be dispensed when a loading dose is prescribed

**SUBSEQUENT MONTHLY DOSE<sup>1</sup>:**

- Subsequent months: **120 mg** SC injection once per month

**EPISODIC CLUSTER HEADACHE<sup>1</sup>**

- **Method of administration:** Prefilled syringe
- **Monthly dosing strength:** 300 mg

Recommended dosing for Emgality during an active cluster period—no titration required<sup>1a</sup>**RECOMMENDED DOSING<sup>1</sup>:**

- **300 mg** administered as 3 consecutive SC injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period
  - 300 mg dose; this comes in 3 x 100 mg prefilled syringes
  - These 3 syringes are administered subcutaneously, one after another
- Patients begin treatment at the onset of a cluster period
- Patients take this **300 mg** dose every month until their cluster period ends

<sup>a</sup>The Emgality Pen and prefilled syringe needles are 27 gauge x 1/2 inch.<sup>3,4</sup>  
CGRP=calcitonin gene-related peptide; SC=subcutaneous.

**INDICATIONS**

Emgality is a calcitonin gene-related peptide antagonist indicated in adults for the preventive treatment of migraine and for the treatment of episodic cluster headache.

**SELECT IMPORTANT SAFETY INFORMATION****Contraindications**

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Please see **Important Safety Information** on the following page. See **Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use** included with the device.

**Emgality**<sup>®</sup>  
(galcanezumab-gnlm)  
120 mg injection/300 mg injection

**MORE  
IS POSSIBLE**

# HOW TO LOCATE AND PRESCRIBE EMGALITY USING AN EMR SYSTEM



Search for “Emgality”



In the EMR system, select the formulation for your patient’s diagnosis<sup>1</sup>:

Emgality Pen 120 mg/mL SC injection	NDC 0002-1436-11	Quantity: 1 per box
Emgality Syringe 120 mg/mL SC injection	NDC 0002-2377-11	Quantity: 1 per box
Emgality Syringe 100 mg/mL SC injection	NDC 0002-3115-09	Quantity: 3 per box



Prescribe the appropriate dose for your patient:

## Emgality 120 mg for migraine

### Loading Dose

*(Use only if the patient does not begin treatment with a Loading Dose Kit [sample]<sup>a</sup> in the office)*

**Dispense:** 2 pens or syringes at once with 0 refills

### Maintenance Dose

*(Use for all patients with migraine)*

**Dispense:** 1 pen or syringe once monthly with 10 refills

## Emgality 300 mg for episodic cluster headache

### Recommended Dosing

#### Sig:

3 SC injections once monthly during an active cluster period

#### Dispense:

(3) 100 mg prefilled syringes with 3 refills



<sup>a</sup>Loading Dose Kits (samples) are intended to establish safety and efficacy for a patient.

EMR=Electronic Medical Record.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

### WARNINGS AND PRECAUTIONS

#### Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

#### ADVERSE REACTIONS

The most common adverse reactions (incidence  $\geq 2\%$  and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

**Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.**

GZ HCP ISI 10DEC2019

**References:** 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.

3. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0071.



Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.  
PP-GZ-US-1079 12/2019 ©Lilly USA, LLC 2019. All rights reserved.

**Emgality**<sup>®</sup>  
(galcanezumab-gnlm)  
120 mg injection/300 mg injection

**MORE  
IS POSSIBLE**